热点栏目 自选股 数据中心 行情中心 资金流向 模拟交易

客户端

　　欧康维视生物-B（01477）发布公告，截至2024年12月31日止年度，收益约4.08亿元-4.20亿元人民币，同比增长65.6%-70.5%。

　　2024年收益的大幅增长主要由于：公司完成了对Alcon转让产品的收购及获许可产品的授权引进，显著提升公司的收益规模；公司于销售其他眼科医药产品产生的收益大幅增加。

海量资讯、精准解读，尽在新浪财经APP

责任编辑：卢昱君

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.